Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
Want to cut your energy bills? Here’s how five experts are doing it 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
ALAMEDA, Calif., March 01, 2017 -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood based tests for the early detection of cancer, announced today that William Annett, Chief Executive Officer, is scheduled to present an overview of the company and its progress at the Cowen and Company 37th Annual Health Care Conference in Boston, MA. The presentation will begin at 9:20 a.m. ET on Wednesday, March 8th, 2017 at the Boston Marriott Copley Place.
Please note the attendance at the conference is by invitation only. Investors interested in scheduling a one-on-one meeting with OncoCyte’s management during the conference should contact their Cowen representative.
A live audio and/or webcast and subsequent archived replay of OncoCyte’s presentations may be accessed via the Investors section of the Company’s website under “Events & Presentations” at http://investors.oncocyte.com/. The replay will be available for 90 days after the event.
About OncoCyte Corporation
OncoCyte is focused on the development and commercialization of novel, non-invasive blood and urine (“liquid biopsy”) diagnostic tests for the early detection of cancer to improve health outcomes through earlier diagnoses, to reduce the cost of care through the avoidance of more costly diagnostic procedures, including invasive biopsy and cystoscopic procedures, and to improve the quality of life for cancer patients.
While current biopsy tests use invasive surgical procedures to provide tissue samples in order to determine if a tumor is benign or malignant, OncoCyte is developing a next generation of diagnostic tests that will be based on liquid biopsies using blood or urine samples. OncoCyte’s pipeline products are intended to be confirmatory diagnostics for lung, bladder and breast cancer. OncoCyte’s diagnostic tests are being developed using proprietary sets of genetic and protein biomarkers that are differentially expressed in specific types of cancer. For more information visit www.oncocyte.com.
Investor Contact: EVC Group, Inc. Michael Polyviou/Doug Sherk 212-850-6020/646-445-4800 [email protected] / [email protected]
